Shares of Health Care sector company Vertex Pharmaceuticals moved -0.6% today, and are now trading at a price of $325.83. The large-cap stock's daily volume was 69,426 compared to its average volume of 1,194,263. The S&P 500 index returned a 0.0% performance.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). The company is based in Boston and has 4,800 full time employees. Its market capitalization is $83,930,218,496.
26 analysts are following Vertex Pharmaceuticals and have set target prices ranging from $280.0 to $439.0 per share. On average, they have given the company a rating of buy. At today's prices, VRTX is trading -2.86% away from its average analyst target price of $335.42 per share.
Over the last year, VRTX's share price has increased by 16.0%, which represents a difference of 23.0% when compared to the S&P 500. The stock's 52 week high is $335.0 per share whereas its 52 week low is $233.01. With an average free cash flow of $2,705,321,500.0 that have been growing at an average rate of 27.3% over the last four years, Vertex Pharmaceuticals is in a position to continue its strong stock performance trend.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 4,129,900 | -204,700 | 3,925,200 | 62.97 |
| 2021-12-31 | 2,643,500 | -235,000 | 2,408,500 | -19.55 |
| 2020-12-31 | 3,253,505 | -259,798 | 2,993,707 | 100.4 |
| 2019-12-31 | 1,569,330 | -75,451 | 1,493,879 | n/a |
